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Transforming growth factor-beta (TGFβ) is a pleiotropic multifunctional cytokine that regulates
several essential cellular processes in many parts of the body including the cornea. Three isoforms
of TGFβ are known in mammals and the human cornea expresses all of them. TGFβ1 has been
shown to play a central role in scar formation in adult corneas whereas TGFβ2 and TGFβ3 have
been implicated to play a critical role in corneal development and scarless wound healing during
embryogenesis. The biological effects of TGFβ in the cornea have been shown to follow SMAD
dependent as well as SMAD-independent signaling pathways depending upon cellular responses
and microenvironment. Corneal TGFβ expression is necessary for maintaining corneal integrity
and corneal wound healing. On the other hand, TGFβ is perhaps the most important cytokine in
the pathogenesis of fibrotic disease in the cornea. Although the transformation of keratocytes to
myofibroblasts induced by TGFβ is largely believed to cause corneal fibrosis or scarring, the
precise molecular mechanism(s) involved in this process is still unknown. Currently no drugs are
available to treat corneal scarring effectively without causing significant side effects. Many
approaches to treat TGFβ-mediated corneal scarring are under investigation. These include
blocking of TGFβ, TGFβ receptor, TGFβ function and/or TGFβ maturation. Other strategies such
as modulating keratocyte proliferation, apoptosis, transcription and DNA condensation are also
being investigated. The potential of gene therapy to neutralize the pathologic effects of TGFβ has
also been demonstrated recently.
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1. INTRODUCTION
Researchers discovered a new cytokine with the capability to transform fibroblasts in 1983
while studying epidermal and platelet derived growth factors in rat fibroblasts [1–2]. It has
been almost three decades since transforming growth factor beta (TGFβ) was characterized
as a distinct molecular entity after isolation from bovine kidney, human placenta, and human
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platelets. Originally called sarcoma growth factor, TGFβ was first isolated from neoplastic
mouse tissue by Moloney sarcoma virus [3]. The TGFβ superfamily is made up of
multifunctional cytokines that affect different cells and play a central role in wound healing
and fibrosis of various organs including the cornea [4–5]. The TGFβ superfamily represents
an extremely complex group of proteins in terms of structure, nomenclature, function,
receptor types, sequence homology, and signaling pathways [1,6]. TGFβ proteins are found
in scores of multicellular organisms in nature highlighting the importance of this cytokine
family [7,8]. TGFβ elicits different responses depending on the context of action,
concentration in different organs, and presence or absence of other growth factors
influencing cellular and immunological activity.
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The majority of cell types produce TGFβ. TGFβ is initially formed as precursor TGFβ
containing the latency-associated protein and the latent TGF-binding protein. The
extracellular activation of this complex is crucial in TGFβ-regulated biological activity.
Upon activation, TGFβ transduces its signal through cooperative binding with two types of
membrane bound TGFβ receptors and communicates the signals from the cell membrane to
the nucleus via Smad-dependent or Smad-independent pathways [9]. The TGFβ superfamily
includes three isoforms of TGFβ, five activins, the Mullerian inhibiting substance, and eight
or more bone morphogenetic proteins (BMP) encoded by different genes. TGFβ cytokines
are involved in wound repair and many other vital pre- and postnatal physiological processes
such as cellular proliferation, migration, differentiation, apoptosis, and extracellular matrix
(ECM) production in various tissues including the cornea [10–12]. TGFβ is linked to a
number of human diseases and pathological processes of many organ systems including
autoimmune disease, oncogenesis, atherosclerosis, fibrosis of the lungs, liver, kidneys, and
skin, and corneal scarring and dystrophy [13–16]. In this review, we will first discuss TGFβ
isoforms, biosynthesis, maturation, signal transduction, and biological function. Then, we
will discuss TGFβ’s role in corneal homeostasis and wound healing followed by its clinical
significance in the pathogenesis of corneal disease and treatment approaches to control
pathologic effects of TGFβ.

2. TGFβ ISOFORMS
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Five TGFβ isoforms have been identified in vertebrates. Three isoforms of TGFβ (β1, β2,
and β3) have been identified in mammals while two additional isoforms have been reported,
namely TGFβ4 and β5 in birds and amphibians respectively [6,17–18]. All isoforms of
mammalian TGFβ are 25 kDa homodimeric proteins and share an extensive similarity in
their amino acid sequences although subtle differences exist [19–20]. For instance, TGFβ1
shows 75% similarity to TGFβ2, and about 80% to TGFβ3 whereas TGFβ2 has
approximately 80% similarity to TGFβ3 [6]. Although these isoforms are homologues their
amino acid sequences are encoded by three distinct genes suggesting that they may have
different functions. First, the disulfide-linked functional protein, a monomer made up of two
polypeptide chains, comes in either a homo- or heterodimer flavor. Second, the monomer is
produced as the C-terminal region of a precursor molecule that also houses a propeptide and
a petite N-terminal sequence required for secretion. Finally, all TGFβ superfamily members
share a conserved C-terminal seven-cysteine domain as part of the monomer’s primary
structure essential for dimerization and protein stability [6].
TGFβ is ubiquitously expressed by many cell types such as fibroblasts, endothelium,
epithelium, smooth muscle cells, etc. Moreover, it is released by immune cells and detected
in wound fluid especially during inflammation and tissue repair. Although all three TGFβ
isoforms participate in wound healing TGFβ1 plays a dominant role in the wound repair
process while TGFβ2 and TGFβ3 have been shown to play a key role in embryonic
development and scarless wound healing [5,21–25].
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The cornea and many other anterior eye segment tissues such as limbus, conjunctiva, and
tear fluid have been shown to express different TGFβ isoforms and their receptors [26–27].
This insinuates the importance of the TGFβ in the eye as will be described later.

3. TGFβ BIOSYNTHESIS AND MATURATION
The biosynthesis and maturation of TGFβ is essential for its biological function. TGFβ is
released as a large inactive precursor lacking the ability to bind to its cell surface receptors
[28]. All three TGFβ isoforms have differences in precursor nucleotide sequence, precursor
amino acid, gene location, and gene expression site as shown in Table (1).
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The inactive TGFβ precursor consists of 390–442 amino acids with three specialized regions
made up of an N-terminal hydrophobic signal peptide region, the latency-associated peptide
region of 249 amino acids, and the C-terminal region, a potentially bioactive TGFβ region
consisting of 112 amino acids (Fig. (1)). The inactive TGFβ precursor is processed in the
Golgi apparatus by endopeptidases, which cleave it at an Arg-X-X-Arg site (X=any amino
acid) leading to the formation of a small latent complex. This complex, which contains a
mature TGFβ homodimer noncovalently attached to two latency-associated peptides, is
usually secreted from the cell with latent TGFβ binding protein as the large latent complex
[29]. Latent TGFβ binding protein anchors inactive TGFβ to the ECM requiring proteolytic
cleavage for conversion to mature TGFβ. Final activation of TGFβ involves the release of
bioactive TGFβ from the latent complex via the interaction of latency-associated peptide
with various proteins. Physical interactions with thrombospondin-1 or proteolytic cleavage
brought about by plasmin, thrombin, endoglycosylase, or plasma transglutaminase causes a
change in latency-associated peptide conformation liberating mature TGFβ [30] (Fig. (2)). In
addition, recent studies evaluated the role of integrins in latent TGFβ activation and also
showed both proteolytic and non-proteolytic (latent TGFβ conformational change via
physical interaction) mechanisms [31].
Following the activation of bioactive TGFβ, a 25 kDa protein made up of two polypeptides
of 12.5 kDa, signal transduction via different molecular signaling pathways may proceed.

4. TGFβ SIGNAL TRANSDUCTION
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TGFβ functions as a regulatory cytokine and relays its commands from the cell surface to
the nucleus by molecular signal transduction. Upon binding to cell-surface receptors, TGFβ
ligands stimulate the assembly of serine/threonine kinase complexes which inaugurate signal
transduction by cytoplasmic protein phosphorylation. This signal is then shuttled to the
nucleus where it activates or suppresses target gene transcription leading to different cellular
responses. The members of the TGFβ signal response incorporate Smad-dependent or Smadindependent signaling pathways depending on cell type.
4.1 SMAD DEPENDENT SIGNALING
Smad signaling pathway has been widely elucidated for the signaling of the TGFβ in
regulating diverse cellular processes [5,25, and 33]. TGFβ transduces its signal across the
plasma membrane by way of specific cell surface receptors known as TGFβ receptors [34].
Based on their structure, function, and electrophoretic mobility, the TGFβ receptor family is
divided into three subfamilies: type I, II, and III receptors [1,6–7].
Type I receptors (TGFβR1) have been found to have a higher level of sequence similarity
than type II receptors (TGFβR2), particularly in the kinase domain. TGFβR1 and TGFβR2
mainly affect the transduction of signals via serine-threonine membrane kinases that
phosphorylate the hydroxyl site of serine-threonine on the target cell. Immediately upstream

Curr Mol Med. Author manuscript; available in PMC 2011 March 4.

Tandon et al.

Page 4

NIH-PA Author Manuscript

from its kinase domain, TGFβR1 has a conserved 30 amino acid region, the “juxtamembrane
glycine-serine domain”, which play important role in TGFβR1 activation [35–36]. For
phosphorylation, TGFβR1 requires activation by TGFβR2 to trigger its kinase function
whereas TGFβR2 boasts intrinsic kinase activity. Furthermore, TGFβR1 requires TGFβR2
for ligand binding [37–38]. After phosphorylation, TGFβR1 phosphorylates and activates
the highly-conserved cytoplasmic proteins of the Smad family. Besides TGFβR1 and
TGFβR2, a third TGFβ receptor also exists. TGFβ receptor III (TGFβR3) is a
transmembrane proteoglycan also known as betaglycan [39]. TGFβR3 binds to all three
mammalian isoforms via its core protein and has a molecular weight ranging from 250–300
kDa. Betaglycan has been reported to be a mixture of heparan sulfate and chondroitin sulfate
glycosaminoglycan [40,41]. Along with endoglin, it is found to have the unique property of
binding TGFβ with high affinity. There is also evidence that the highest level of sequence
similarity between betaglycan and endoglin is found in the cytoplasmic and transmembrane
domains [42].
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Previously Cheiftz and collaborators evaluated the ligand binding property of betaglycan
and its presence in serum and ECM [18]. Many studies have revealed that TGFβR3 is not
directly involved in TGFβ signal transduction. However, after binding to various TGFβ
superfamily members at the cell surface, it may act as a ligand reservoir for TGFβ receptors.
Therefore, even though TGFβR3 is not believed to take part in signal transduction directly,
it allows high affinity binding to TGFβR2. TGFβ1 and β3 bind TGFβR2 to initiate signal
transduction whereas TGFβ2 requires TGFβR3 in order to bind TGFβR2 [43]. Upon binding
to its corresponding receptor, TGFβ elicits its signals through Smad transducers (Fig. (3)).
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What are SMADS?—SMADs are evolutionarily conserved proteins that modulate the
activity of the large family of proteins related to TGFβ. Smad proteins, the only substrates
for type I receptor kinases, were first identified as the gene products of Drosophila
melanogaster Mad and Caenorhabditis elegans Sma genes. The term Smad was thus derived
from Sma and Mad (Mothers against decapentaplegic) gene homologues in C. elegans and
D. melanogaster [44,45]. The Smad family is classified according to function and consists
of three main categories. These include receptor-regulated Smads (R-Smads), common
mediator Smads (co-Smads), and inhibitory Smads (I-Smads). R-Smads (Smads1–3, Smad5,
and Smad8) are ligand specific and become phosphorylated after directly interacting with
activated TGFβR1. The receptor regulated Smads, Smad2 and Smad3, are mainly
phosphorylated by TGFβ cytokines and activin receptors while Smad1, Smad5, and Smad8
are phosphorylated by BMP receptors [46]. Smad4, a co-Smad, is a common intermediary of
all TGFβ superfamily members including TGFβ, activins, and BMP receptors for signal
transduction from cell membrane to the nucleus. Furthermore Smad4 is essential for nucleus
entry by associating with a receptor phosphorylated R-Smad. Finally, the third group
comprises I-Smads also termed anti-Smads. I-Smads, Smad6 and Smad7, antagonize TGFβ
signaling by interfering with the activation of R-Smads [47]. It has also been clearly noted
that I-Smads demonstrate their action by associating with TGFβR1 and for the most part
inhibit R-Smad recruitment by phosphorylation. In differentiating between the I-Smads, it
has been reported that Smad7 mainly inhibits TGFβ and activin signaling while Smad6
inhibits BMP signaling in different cellular processes. Generally, Smads remain in their
basal state in the cytoplasm to allow for their timely exposure to activated receptors. Besides
this, type E3 ubiquitin ligases known as Smad ubiquitination regulatory factors-1/2
(Smurf-1/2), are also important in the regulation of different TGFβ signaling pathways [48].
By and large Smurf-1/2 targets TGFβR1, TGFβR2, and various Smads for proteasomemediated degradation.
Structurally Smads are characterized by two highly conserved proline-rich globular
domains, N-terminal Mad homology 1 (MH-1) and C-terminal Mad homology 2 (MH-2),
Curr Mol Med. Author manuscript; available in PMC 2011 March 4.
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that are held together by a nonconserved variable linker region. The MH1 domain
recognizes the DNA sequence CAGAC whereas the MH2 domain mainly binds
transcriptional coactivators.
The MH-1 and MH-2 domains of R-Smads and co-Smads show conserved regions as does
the MH-2 domain of I-Smads. The MH-1 domain of I-Smads however, is not conserved and
shows variation among species. Variability also exists in the functions of different MH-1
and MH-2 domains. For instance, the MH-1 domain of R-Smads binds DNA, while the
MH-2 domain participates in intermolecular protein-protein interactions and is responsible
for activating transcription. Moreover, studies have shown that the MH-1 domain of Smad3
and Smad4 possesses DNA binding ability whereas Smad2’s MH-1 domain does not
directly bind to DNA efficiently [49–50]. Vasaliki and cohorts recently showed that amino
acids glutamine 222 and proline 229 of the conserved variable linker region of Smad
proteins plays principle roles in homo- as well as hetero-oligomerization and nuclear
accumulation [51]. At the extreme C-terminus of the MH-2 domain, R-Smads contain a
phosphorylation motif, SSxS, which is the site of Smad2 and Smad3 phosphorylation by
TGFβR1 (Fig. (4)). Specifically, the last two Ser residues of the C-terminal SSxS motif are
important and provide the site for the phosphorylation of R-Smads [52].
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The activated TGFβR1 then specifically recognizes and phosphorylates R-Smads, recruited
by Smad anchor for receptor activation (SARA) that presents R-Smads as substrates to the
activated TGFβ receptor complex. R-Smad phosphorylation decreases its affinity for SARA
and leads to the formation of a heterocomplex with the unique co-Smad, Smad4. The
activated R-Smads form a heterotrimeric complex with Smad4, and are then rapidly
translocated to the nucleus. Smad4 translocates to the nucleus only when combined with RSmads unlike R-Smads which may autonomously enter the nucleus from the cytoplasm
without Smad4. When Smad4 is blocked or absent however, R-Smads may translocate but
lack the ability to complete the signal to the nucleus via gene expression. This finding
suggests that the main role of Smad4 is to regulate transcription rather than to transmit
TGFβ signals from the cytoplasm to the nucleus. In many ways, the Smad heterotrimeric
complex is viewed as a coactivator for various transcription factors. This is because it
activates or suppresses transcription by way of its interactions with coactivators CBP/p300
[53–54]. After entrance into the nucleus, the complex interacts at the promoter site with
transcription factors that contain sequence-specific DNA binding affinity to regulate gene
expression. Here the heterotrimeric complexes essentially activate downstream responses
and may act as transcriptional factors themselves controlled by a balance between
transcriptional co-activators and co-repressors. In short, the heterotrimeric complex may
recruit co-activators to stimulate transcription or recruit co-repressors to inhibit transcription
leading to the expression of genes responsible for different cellular responses.
4.2 SMAD INDEPENDENT SIGNALING PATHWAY
Accumulating evidence over the past few years indicates that TGFβ may signal through
several pathways besides the Smad cascade for modulation of cell activity during both
embryonic development and corneal wound healing. One such study conducted by the Saika
group (2004) reported a lack of Smad3/4 localization in the nuclei of migrating corneal
epithelium showing that the TGFβ/Smad pathway may not be directly involved in the
regulation of cell proliferation. This is evident by the fact that TGFβ can activate several
mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinases
(ERKs), c-Jun N-terminal kinases (JNKs), and p38 kinases [55–56]. TGFβ also activates the
phosphatidylinositol-3 kinase (PI-3) pathway, and in certain cells, signaling involving
PP2Aphosphatase and RhoA (Fig. (5)). The MAPK signaling cassette is composed of the
ERK, p38, and JNK/SAPK pathways which operate in parallel with one another. The
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MAPK pathways in mouse, rabbit, and human corneal epithelium mediate cell migration of
corneal epithelium [57].
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5. TGFβ BIOLOGICAL FUNCTION
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5.1 TGFβ’S ROLE IN FIBROSIS AND OTHER DISEASES

TGFβ affects a vast range of biological processes. It regulates cell replication, proliferation,
differentiation, and migration [32,58, and 59]. TGFβ also controls cell cycle progression,
programmed cell death, ECM production, immune tolerance, inflammation, angiogenesis,
hematopoiesis, bone formation, wound healing, and fibrosis [60–62]. In addition, TGFβ
stimulates collagen synthesis and the production of several key proteins such as tenascins,
fibronectin, thrombospondin, proteoglycans, tissue inhibitor of metalloprotease-1 (TIMP-1),
and plasminogen activator inhibitor-1 (PAI-1) [10,63]. Furthermore, TGFβ is known to act
in an isoform-dependent way to protect neurons. In many instances TGFβ has two-way
functional capabilities allowing it to inhibit various cellular processes in one context while
stimulating the same processes in another. For example, TGFβ functions as both a stimulator
and inhibitor of cellular replication thus controlling ECM production [64]. As is evident,
TGFβ has various effects in different cells in diverse settings. It is essential for the
maintenance of life (tissue homeostasis) as it mediates tissue growth and development as
well as tissue wound healing following injury. Overexpression of this vital growth factor
however, may lead to disease and in some instances, death.
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Following an injury, the body expends a great deal of energy in an effort to repair itself and
restore tissue function. This leads to healing via a fibroproliferative response which entails
TGFβ-mediated deposition of excessive collagen along with ECM. This type of wound
healing involves inflammation, angiogenesis, migration and proliferation of fibroblasts, and
connective tissue remodeling that leads to scarring. Previous studies have identified TGFβ1
and TGFβ2 as potent stimulators of fibrosis in the skin [65–66]. After sustaining an injury,
TGFβ regulates damage repair and endeavors to restore previous tissue function and
morphology. This maintenance of tissue homeostasis involves delicate interactions among
TGFβ, the ECM, and different cells. This restores vital barrier function, integrity, and tensile
strength of the tissue [67–69]. Unlike adult tissue, fetal tissue exhibits the ability to swiftly
heal skin wounds and render them scar free. This is thought to be due to several mechanistic
differences that exist between fetal and adult wound healing as well as TGFβ levels [66,70].
For instance, adult tissue is contaminated and desiccated while fetal tissue is surrounded by
amniotic fluid and is housed in a germ-free environment. Additionally, adult tissue is fully
differentiated and fibroblast migration along with reepithelialization occurs at a much slower
rate than in fetal tissue. Furthermore, in adult wounds there is a massive inflammatory
response compared with fetal wounds. Potent platelet degranulation of active cytokines,
especially TGFβ, is also visible in adult wounds while a reduced amount is seen in fetal
wounds [71]. In regards to specific TGFβ isoforms, TGFβ3 has been shown to predominate
in fetal wound healing where TGFβ action is modulated by fibromodulin. However, this is
not the case in adults as TGFβ1 is the chief isoform and is modulated by proteoglycans
including decorin. This suggests that scarless wound healing may be influenced by the
relative ratio of different TGFβ isoforms in particular TGFβ1 and β3 [72]. Past studies have
also found that the addition of exogenous TGFβ to fetal wounds switches the scarless tissue
regeneration healing process to adult-like wound healing where scarring results [30,73]. This
also reemphasizes the importance of various isoforms of TGFβ in homeostasis, wound
repair, and fibrosis.
The disturbance of TGFβ homeostasis may result in various pathological entities including
fibrosis. TGFβ deficiency has been linked with defective wound repair, as well as

Curr Mol Med. Author manuscript; available in PMC 2011 March 4.

Tandon et al.

Page 7

autoimmune diseases, inflammation, atherosclerosis, and oncogenesis. Excessive TGFβ
levels have been associated with hypertension, angiogenesis, and cancer [74].
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TGFβ has bidirectional capabilities that are very much context specific. In various
physiologic and disease states, it may function as an inhibitor of various cellular processes in
one instance but promote the same processes in another. In the immune system for example,
TGFβ regulates leukocyte activation along with chemotaxis. By so doing, it protects the
body from the development of autoimmune diseases while allowing the immune system to
combat foreign pathogens. If TGFβ is overexpressed however, immunopathologies such as
cancer may result. Early in oncogenesis, TGFβ operates as an anti-mitogenic factor and a
tumor suppressor [75]. Later on as the cancer progresses however, the once-protective
cytokine promotes angiogenesis as well as myofibroblast transformation furthering tumor
expansion, advancement, and metastasis [76]. In other systems, an increase or decrease in
TGFβ may lead to disease in both cases. This is seen in chronic obstructive pulmonary
disease where overactive TGFβ signaling leads to small airway disease while decreased
TGFβ signaling triggers parenchymal tissue obliteration in emphysema [77]. We, along with
others, speculate that assorted gene transcription regulation is thought to be the avenue by
which TGFβ exerts contradictory effects.
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As discussed earlier, TGFβ also directs ECM production as it is a stimulator and inhibitor of
cell replication [64]. TGFβ stimulates the synthesis of collagens, fibronectin, proteoglycans,
thrombospondin, PAI-1 and TIMP-1. The increased secretion of PAI-1 and MMP-9 brought
about by TGFβ2 has been shown to play a role in prostate cancer where TGFβ mainly
induces apoptosis of the epithelium. In the developing embryo TGFβ has been reported to be
a powerful inhibitor of hematopoietic stem cell proliferation. Nevertheless, its role in adult
hematopoiesis has yet to be elucidated. The role of TGFβ superfamily in myocardial
infarction including infarct healing, cardiac repair, and remodeling has also been reported
although the molecular mechanism is still unknown [78].
5.2 TGFβ EXPRESSION AND LOCALIZATION IN THE CORNEA
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TGFβ is expressed in the cornea reflecting its complex role in maintaining corneal integrity
and promoting corneal wound healing [79–80]. The cornea, a transparent avascular tissue
that covers and protects the front surface of the eye, is made up of three cell layers and two
membranes from anterior to posterior: epithelium, epithelial basement membrane
(Bowman’s layer), stroma, Descemet’s membrane, and endothelium. Although
constitutively expressed by the uninjured cornea, TGFβ has been reported in varying
quantities in different layers of the cornea depending on the condition of the cornea [80]. For
example, TGFβ is normally restricted to healthy intact corneal epithelium but is secreted
into the stroma during wound healing [81]. In the healthy cornea TGFβ1 is detected inside
epithelial cells while the isoforms TGFβ2 and β3 are present in the extracellular
environment [15]. In the wounded cornea TGFβ1 is the minor isoform observed while
TGFβ2, the major mediator of the corneal fibrotic response, is detected in large amounts.
Previous studies report that both TGFβ1 and β2 are seen within the corneal epithelium and
stroma in the injured cornea while TGFβ3 is not found in the anterior eye at all [12,82–83].
Recently however, Huh and colleagues reported unique differences in isoform expression
including TGFβ3 following corneal wounding in chick cornea via immunohistochemistry.
TGFβ3 was found in basal cells of regenerating areas as well as uninjured regions of the
cornea after corneal injury while TGFβ1 levels were increased in Bowman’s layer and
TGFβ2 demonstrated strong expression in migrating and proliferating epithelial cells,
fibroblasts, Descemet’s membrane, and the endothelium [80]. Other investigators also hold
that all three isoforms occur after corneal injury and are present in the stroma. Variation in
TGFβ corneal expression also exists among species. For example, TGFβ1 was observed in
Curr Mol Med. Author manuscript; available in PMC 2011 March 4.
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normal chick cornea but was absent in normal and wounded mice corneal epithelium. This
could be due to differences in corneal composition as mice lack Bowman’s layer in the
cornea [84].
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From clinical observation and extensive experimentation, we and other researchers have
postulated that the integrity of Bowman’s layer may play a key part in TGFβ release from
the corneal stroma in corneal wound healing. Upon debriding the corneal epithelium from
Bowman’s layer, cells of the corneal stroma undergo programmed cell death and the stroma
is regenerated via mitosis. This occurs without the hypercellularity and excess ECM
deposition seen in fibrosis as will be discussed in following sections. The expression of
fibrotic markers is observed only if Bowman’s layer is penetrated and the stroma is ablated
after debridement of the corneal epithelium as seen in photorefractive keratectomy (PRK).
Laser-assisted in situ keratomileusis (LASIK) takes advantage of this fact as Bowman’s
layer is only pierced around the borders of a flap. This allows for replacement of dead
keratocytes surrounding the ablated area without stimulating the fibrotic response leading to
subsequent corneal haze [81,85]. A recent study conducted by our lab sought to observe
systematic and time-dependent monitoring of TGFβ following injury using a PRK rabbit
model. Fig. (6) shows time-dependent localization and levels of TGFβ1 in −9.0 D PRKtreated rabbit cornea. PRK caused a significant increase in TGFβ1 in the stroma from day-1
to day-3. The increase in TGFβ1 expression at day 1 and day 3 in the stroma of post-PRK
cornea was found statistically significant (p<0.001 or <0.01) compared to naïve corneas.
Nonetheless, a decline in an elevated level of TGFβ1 was observed after these two time
points as extremely low or no TGFβ1 expression was detected at day 7 or day 14 in the
stroma. As expected TGFβ1 expression was observed in the regenerated epithelium and
basement membrane, which was removed prior to performing PRK. The levels of TGFβ2
expression in the rabbit stroma after PRK injury was markedly different from the TGFβ1,
however, the pattern of change in expression level was similar but not identical as evident
from Fig. (7). Like TGFβ1, the TGFβ2 levels in the anterior stroma at day 1 and day 3 after
PRK was significantly (p<0.01) higher than the naïve controls. This strongly suggests that
TGFβ is essential in initiating the corneal wound healing response and once activated, the
response may prove self-perpetuating.
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All three isoforms are found in different regions of the cornea reflecting their different roles.
Jester and colleagues previously showed the role of TGFβ1 following refractive surgery in
keratocyte activation, myofibroblast transformation and proliferation, and wound healing
[86]. TGFβ2 plays a key role in corneal development (epithelial-mesenchymal interactions)
as well as homeostasis and repair [87]. Following corneal wounding for example, TGFβ2 is
detectable in the central corneal wound region where it is responsible for myofibroblast
transformation, proliferation and stratification that leads to regeneration of corneal epithelial
cells. The mechanism by which this occurs includes migration of activated keratocytes at the
wound edge into the fibrin clot which is largely replaced by fibroblasts that become TGFβ2producing myofibroblasts. Along with TGFβ1 and TGFβ2, TGFβ3 also stimulates epithelial
cell proliferation in the cornea especially in unwounded regions [80].
5.3 TGFβ’S ROLE IN CORNEAL WOUND HEALING AND SCARRING
Wound healing plays an integral part in the maintenance of corneal transparency and is thus
crucial to normal visual function [25]. Corneal injury has been shown to trigger an
unfettered wound healing response that all but induces scarring leading to visual loss.
Corneal scarring is an important ocular pathology and is the third leading cause of blindness
worldwide [88]. Numerous growth factors and cytokines have been found to regulate
corneal wound healing and include TGFβ, connective tissue growth factor, ECM, distinct
cell types, etc. TGFβ is arguably the most important ligand in the pathogenesis of fibrotic
disease in the cornea as well as in the eye as a whole. Examples range from corneal scarring
Curr Mol Med. Author manuscript; available in PMC 2011 March 4.
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to lens capsule fibrosis following cataract surgery to tractional retinal detachment in
proliferative diabetic retinopathy [25]. In addition to being a sequela of corneal infection,
TGFβ-mediated corneal haze development is also apparent following surgical procedures
such as PRK, a common laser eye surgery used globally to correct refractive errors in
humans [4,89]. As shown in Fig (6) and (7), TGFβ1 and TGFβ2 detected immediately
following PRK injury affect keratocyte, fibroblast, and myofibroblast population in the
corneal stroma. This strongly suggests that TGFβ is essential in initiating the corneal wound
healing response and once activated, the response may prove self-perpetuating.
It has been reported that following corneal injury, TGFβ overexpression leads to corneal
turbidity. This is because increased TGFβ levels augment JNK 1/2-mediated connective
tissue growth factor gene expression. Proliferation and migration of ECM proteins collagen
and fibronectin by corneal fibroblasts ensues leading to corneal haze [90]. Specifically, the
release of TGFβ from injured corneal epithelium induces transformation of quiescent
keratocytes into corneal fibroblasts and myofibroblasts, a molecular mechanism known to
cause haze. Myofibroblasts are metabolically active and highly contractile cells with
reduced transparency attributable to decreased intracellular crystallin production [89].
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To date, numerous efforts have been made to identify the mechanism for the effect of TGFβ
on improving healing wounds and epithelialization. Following corneal injury, TGFβ leads to
an increase in pro-fibrotic molecules and cytokines that control the immune response as well
as inflammation. In particular, TGFβ affects chemotaxis of pro-inflammatory cells such as
monocytes, lymphocytes, neutrophils, and fibroblasts as well as the production and
remodeling of ECM, mitosis induction in certain fibroblasts, and angiogenesis [76,91]. Once
fibroblasts commence the proliferation process, collagen production is increased. The
amplified production of collagen coupled with decreased ECM degradation leads to an
increase in scar formation [92].

NIH-PA Author Manuscript

TGFβ1 is responsible for myofibroblastic differentiation, the transdifferentiation of
quiescent keratocytes to fibroblasts and myofibroblasts seen in corneal fibrotic disease
alluded to earlier. Myofibroblast transformation leads to wound contraction and subsequent
aberrant tissue function. Myofibroblasts, which originate from mesenchymal cells or
epithelial cells via epithelial-mesenchymal transition, can be distinguished by the expression
of α-smooth muscle actin (α-SMA) and alter ECM production in corneal wound healing.
Biochemically and morphologically an intermediate between smooth muscle cells and
fibroblasts, myofibroblasts generate a powerful contractile force, essential to wound closure.
Myofibroblastic differentiation brought about by TGFβ1 is often accompanied by gene
expression augmentations of essential wound healing proteins. Examples include
cytoskeletal proteins (α-SMA), ECM proteins (fibronectin, proteoglycans, and collagen),
and inhibitory proteins that deter ECM degradation. Additionally, myofibroblastic
transformation leads to the loss of cell-cell contact between fibroblasts in cell cultures [93].
TGFβ in other areas of the eye in close proximity to the cornea affects corneal scarring. A
recent study showed that increased expression of TGFβ1 in the anterior chamber leads to
myofibroblast transformation in all corneal layers. The loss of corneal homeostasis due to
endothelial damage following injury or surgery deep to the cornea may also play a role in
corneal fibrosis and subsequent corneal opacification. In addition to the aqueous humor in
the anterior chamber, the cornea is also in direct contact with the tear film suggesting that
TGFβ and other cytokines and growth factors present in this layer also influence corneal
wound healing [23].
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TGFβ superfamily members have been implicated in various biological and pathological
processes. Thus corneal haze is a result of TGFβ-modulated wound healing following ocular
infection or trauma including injury and surgery. Current conventional small molecule drug
treatments do not effectively treat corneal scarring and angiogenesis, require repeated drug
application and are associated with side effects. On the horizon, other novel approaches such
as gene therapy are proving to have potential in corneal haze treatment. It is also thought
that the timing of therapy is critical as early treatment is imperative to prevent corneal
scarring. Ongoing experiments in our laboratory are focused on the suppressor functions of
TGFβ1, a potential strategy to treat corneal scarring, and aim to elucidate the unique
molecular mechanisms underlying the role of this vital cytokine in wound healing for
corneal eye disease.
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Presently no effective remedy exists to eliminate corneal scarring without significant
adverse effects. Although topical corticosteroids are frequently utilized in the treatment of
corneal scarring, they are only beneficial short-term, cause many side effects, and seldom
prove efficacious in reducing corneal scarring [94]. Numerous corneal surgeons apply
topical mitomycin C (MMC) prior to PRK to avert laser-induced corneal haze. MMC, an
alkylating chemotherapeutic agent, attempts to limit corneal haze by blocking proliferation
brought about by TGFβ. However, MMC causes several complications such as corneal
endothelial damage, abnormal wound healing, limbal and scleral necrosis, and loss of
keratocytes [95–96]. Netto and colleagues recently demonstrated that topical application of
MMC also inhibits repopulation of keratocytes and establishes an acellular zone in rabbit
corneas up to six months post application [97].
Several other agents such as synthetic inhibitors of metalloproteinase, cyclosporine-A,
vitamin E, diclofenac, etc. have shown some benefit in animal studies. However, their high
toxicity combined with other deleterious side effects limit their use in humans [98–100].
Nerve growth factor and amniotic membrane have also been reported to control corneal scar
and corneal ulcer formation. Even so, clinical trials with nerve growth factor failed to show
significant benefits compared to conventional treatment (tarsorrhaphy or bandage contact
lens) [101–102]. Phototherapeutic keratectomy, a laser surgical technique, has also been
used to treat corneal scarring resulting from gunpowder explosion but leads to undesirable
side effects including hyperopic shift and astigmatism among others. The complications and,
in some cases, toxicity of current practices in the management of corneal scarring illustrates
the inherent risks of these treatments and advocates for the development of safer, improved
pharmacologic agents in reducing corneal haze without serious side effects [98–100].
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We recently tested our hypothesis that agents having inactivation as well as neutralization
properties of TGFβ can inhibit haze progression in the cornea in vivo. We reported that
trichostatin A (TSA), a histone deacetylase inhibitor that suppresses TGFβ-induced
fibrogenesis in many nonocular tissues, reduces corneal haze [103]. Although not currently
in clinical use, TSA may be incorporated into treatment of ophthalmology patients to reduce
corneal haze in the near future. In addition to TSA, our laboratory also studied vorinostat, an
FDA-approved derivative of TSA presently in clinical use for the treatment of progressive,
persistent, or recurrent cutaneous T-cell lymphoma. In preliminary experiments, vorinostat
showed similar potential to TSA in impeding corneal haze development [a]. Besides
vorinostat, moxifloxacin has been shown to inhibit myofibroblast development by blocking
TGFβRI [b].

aLopez, V., Tovey, J., Sharma, A., Waggoner, M., Cowden, J.W. and Mohan, R.R. Vorinostat Effectively Reduces TGFβ-Mediated
Myofibroblast Formation in the Cornea. Program Summary of ARVO 2010 Meeting, Fort Lauderdale, Florida, May 2–l6, 2010; p. 57.
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The feasibility of treating corneal scarring via gene therapy, an innovative treatment
modality approach, has also been demonstrated [104]. Gene therapy in the cornea seeks to
employ appropriate vectors (viral or non-viral) to transfer genes to the cornea in order to
increase or decrease the expression of a particular protein, cytokine, or growth factor that
will in turn modulate corneal disease. In the case of corneal scarring, the cytokine of concern
is none other than TGFβ. We conjecture that genes blocking TGFβ activity will prevent
myofibroblast transformation and thus scarring in the cornea in vivo. We recently
demonstrated inhibition of TGFβ-mediated transdifferentiation of corneal keratocytes to
myofibroblasts with decorin, a natural modulator of TGFβ, using an in vitro model. In our
study we demonstrated the presence of decorin mRNA and protein in rabbit cornea. Studies
in non-ocular tissues have demonstrated that collagen-bound decorin does not efficiently
neutralize TGFβ. Since decorin in the cornea is bound to collagen, it may not be available to
neutralize PRK-induced increased TGFβ levels in the corneal stroma. Therefore, PRKinduced corneal haze may represent an imbalance between TGFβ and its endogenous
inhibitor decorin [105]. Another approach that has been tested in preventing corneal scarring
is the blockade of cyclins and cyclin-dependent kinases, both of which play an active role in
controlling cell division. Further studies are needed to delineate the utility of decorin in
treating corneal scarring.
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Other avenues in gene therapy endeavor to block certain targets in the TGFβ signaling
pathway. In this manner, beneficial effects of TGFβ such as JNK-dependent fibronectinmediated epithelialization of wounds are preserved while detrimental effects of TGFβ such
as Smad3-induced collagen overproduction are inhibited. Examples include blocking
specific R-Smads, such as Smad3. In wound healing experiments, it was found that the
overexpression of I-Smads, like Smad7, had similar effects to blocking Smad3 in reducing
TGFβ1 gene expression. In addition to its effects in the cytoplasm, Smad7 may block
transcription factors in the nucleus. Major advantages of gene therapy include lower dose for
effect, lower cost, increased efficiency, and a longer period of gene expression eliminating
the need for frequent repeated injections or applications which can further hamper wound
healing. A concern with gene therapy however, is possible harmful side effects. Although
gene transfer with viral vectors may result in a secondary inflammatory reaction, this can be
circumvented with the utilization of non-viral vectors like plasmid DNA [92].
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Another approach in gene therapy for corneal scarring is the use of soluble TGFβR2.
Soluble TGFβR2 blocks TGFβ activity by binding TGFβ thus rendering it unable to bind its
cell surface receptor. In corneal injury model, a single dose of recombinant adenovirus
encoding for soluble TGFβR2 decreased corneal opacification as well as inflammation, and
neovascularization [104]. Unfortunately, like other gene therapy methods, this approach is
unregulated and untargeted leading to numerous adverse effects. Although these examples
show the potential of gene therapy in treating corneal scarring, they also point out major
obstacles, like safety profile, that need to be addressed if gene therapy is to make the
transition from the laboratory to clinical practice in patients. Our lab is working to optimize
tissue-selective targeted gene delivery into keratocytes employing AAV vectors that are
non-pathogenic to humans. With the utilization of a specific mutant vector and specialized
surgical techniques, we have demonstrated successful transduction of genes into the corneal
endothelium.
On the protein level, TGFβ antagonists such as monoclonal antibodies are also showing
promise in treating corneal scarring. Earlier, Shah and collaborators reported results from a
ground-breaking study where anti-TGFβ1 and β2 antibodies were shown to inhibit
bChang, S.W., Chen, T.C., Wang, T.Y., and Chou, S.F. Moxifloxacin Suppresses Myofibroblast Differentiation via Blocking TGFbetaRI on Corneal Fibroblasts. Program Summary of ARVO 2010 Meeting, Fort Lauderdale, Florida, May 2–l6, 2010; p 57.
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formation of cutaneous scars in rodent wounds. Not only did the antibody-treated wounds
demonstrate decreased TGFβ1, collagen, and fibronectin levels, they also showed an
increase in normal cutaneous structure, and equal tensile strength as compared to other
wounds. A follow up study where TGFβ3 was added to the wounds also showed decreased
cutaneous scarring [106]. Furthermore, it was established by the same group that early
treatment is paramount in decreasing scar formation as the first dose of TGFβ stimulates
TGFβ overproduction. This comes about by way of chemotaxis and autoinduction which in
turn induces collagen overproduction and fibroblast proliferation while simultaneously
inhibiting ECM breakdown [92].

NIH-PA Author Manuscript

Carrington and cohorts found that in the cornea TGFβ1 delays re-epithelialization,
accelerates keratocyte proliferation, increases repopulation of cells around the wound, and
encourages the transformation of keratocytes to myofibroblasts [107]. In contrast, they also
found that the anti-TGFβ1 monoclonal antibody CAT-192 enhances re-epithelialization of
the cornea while reducing stromal repopulation. Comparable results to CAT-192 were also
reported with low doses of IL-10 and exogenous TGFβ3, although TGFβ3 elicited little
effect on corneal re-epithelialization. This recognizes IL-10 and TGFβ3 as potential agents
in treating and preventing fibrosis in the cornea [107]. Although monoclonal antibodies may
seem to be an optimum treatment choice for corneal scarring, a major problem
accompanying their use is their stability at room temperature. In addition to monoclonal
antibodies, treatment for corneal scarring on the protein level includes biglycan as well as
soluble TGFβ receptors and decorin as explained above [96].
Another approach to thwart the effects of TGFβ may be to block its maturation from latent
TGFβ. Zieske and cohorts demonstrated in a mouse model that αVβ6 integrin, a key protein
involved in latent TGFβ1 activation by latent-associated peptide cleavage, is increased
during epithelial wound healing. A significant reduction in laminin, α-SMA, and mature
TGFβ1 was seen as well as an increase in large latent TGFβ1 in β6-null mice following
keratectomy. This is another strategy where TGFβ modulation can be achieved [c].
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Corneal wound healing, mediated by various cytokines such as TGFβ, necessitates
functioning stem cells from the adjacent corneoscleral junction also known as the limbus.
The loss of these vital stem cells consequently leads to wound healing difficulties. Although
not well characterized, several signaling pathways including TGFβ control corneal stem
cells. Limbal stem cells have successfully been used in human autograft transplantation in
the past. For example, one study demonstrated that limbal explants containing limbal
epithelial stem cells obtained from the healthy eye of an individual could be transplanted
into the contralateral diseased eye of the patient leading to corneal re-epithelialization along
with regression of both angiogenesis and persistent epithelial defects. This has subsequently
led to the development and utilization of limbal stem cells grown on amniotic membrane as
well as autologous mucosal epithelial cell grafts [108].
Previously, so called ‘‘wandering cells’’ were thought to play a part in tissue repair and
wound healing. Recent stem cell research has revived this idea as reports point to similarities
in the cornea. There is an increasing body of evidence suggesting that wandering cells are
actually stem cells originating from the bone marrow, and can assist in tissue repair in
various tissues including the cornea [81]. Recently a pioneer study demonstrated the
migration of GFP-labeled BM-derived cells into the corneal stroma of mice [109]. It was
shown immunohistochemically that some of the migrating cells were BM-derived dendritic

cBlanco, T., Hutcheon, A.E.K., and Zieske, J.D. Up-Regulation of TGF-β1 by αVβ6 Integrin Enhances Corneal Wound Healing in
Mice. Program Summary of ARVO 2010 Meeting, Fort Lauderdale, Florida, May 2–l6, 2010; p 172
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cells and macrophages [110]. The role of bone marrow–derived stem cells in corneal wound
repair is an area with scant information that will benefit from thorough exploration.
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In conclusion, TGFβ is a remarkable cytokine that plays a vital role in the homeostasis of all
tissues in the human body including the cornea. It is essential for growth and development
before birth and throughout life but can also lead to tissue failure and premature death if
unregulated. Its different isoforms, biosynthesis, maturation, signal transduction involving
the SMAD pathway, and biological function including its role in fibrosis and wound healing
have been well documented. However, other signaling pathways have yet to be completely
elucidated as it has become accepted that cross-talk is evident between pathways. In addition
to regulating numerous other growth factors and cytokines, TGFβ is controlled not only by
itself in a negative feedback manner, but also by other factors. Many of these factors, such
as connective tissue growth factor, have been studied extensively but others have yet to be
afforded the same attention. Importantly, TGFβ may hold the key to scarless tissue repair
thus warranting further investigation. This is especially important in the cornea as TGFβmediated corneal scarring is a leading cause of blindness. Effective treatment of fibrosis and
scarring in the cornea is still under investigation as current modalities offer little resolution
and are plagued with serious side effects. However, with continued research and the
implementation of novel approaches such as targeted gene therapy and stem cell
transplantation, the future seems bright in the field of corneal wound healing.
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Fig. (1).

Schematic representation of the protein structure related to TGFβ. An N-terminal
hydrophobic signal peptide region (30 amino acids), the latent associated peptide (LAP)
(249 amino acids) region and the C-terminal, a mature bioactive TGFβ region.
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Fig. (2).

Schematic representation of TGFβ maturation. Precursor pro-TGFβ is cleaved by
endopeptidase in Golgi apparatus to form small latent complex. This complex then
covalently binds with latent TGFβ binding protein (LTBP) and forms the large latent
complex that is finally released into the ECM as mature TGFβ.
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Fig. (3).
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TGFβ Smad-dependent signaling pathway: TGFβ exerts its effect by binding and activating
type II receptor (TGFβR2) and then type I receptor (TGFβR1). After phosphorylation,
TGFβR2 phosphorylates TGFβR1, which subsequently phosphorylates and activates RSmads (Smad2/3). Activated R-Smads are released from receptors then form a
heterotrimeric complex with co-Smad (Smad4), which is translocated into the nucleus to
regulate transcription of the target gene. I-Smads (Smad6 and Smad7) shows inhibitory
Smad interaction and interfere with the activation of R-Smads while Smurf1/2 targets
TGFβR-1 and TGFβR-2 along with various Smad family proteins for proteasome-mediated
degradation.
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Fig. (4).

Schematic diagram of R-Smad containing MH-1 and MH-2 regions at amino (N) and
carboxyl (C) terminal respectively linked together by variable linker region and specific
phosphorylation motif, SSxS, at C-terminus.
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Fig. (5).

TGFβ Smad-independent Signaling Pathways: TGFβ exerts its effect by binding and
activating type II receptor (TGFβR2) and then type I receptor (TGFβR1). Smad independent
pathways are then activated and include various branches of MAP kinase (MAPK)
pathways, Rho-like GTPase signaling pathways, phosphatidylinositol-3-kinase (PI3K)/AKT
pathways and protein phosphatase 2A (PP2A) pathway. These pathways then regulate gene
transcription in the nucleus. The exact mechanism of activation of these various Smadindependent signaling pathways remains to be elaborated.
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Fig. (6).

Representative immunofluorescence images showing time-dependent expression and
localization of TGFβ1 in −9.0 D PRK-treated rabbit cornea. PRK caused a significant
increase in TGFβ1 in the stroma at day 1 and day 3 (p<0.001 or <0.01) compared to naïve
corneas. The elevated level of TGFβ1 showed progressive decline as extremely low or no
expression was detected at day 7 or day 14 in the stroma. The naïve corneas did not show
any TGFβ1 expression (data not shown). Scale bar denotes 50 µm.
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Fig. (7).

Representative immunofluorescence images showing time-dependent expression and
localization of TGFβ2 in −9.0 D PRK-treated rabbit cornea. PRK induced TGFβ2
expression in the stroma at an early time points (day 1 and day 3) as no expression of
TGFβ2 was detected in naïve corneas (data not shown). Scale bar denotes 50 µm.
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